A major step forward in using Artificial Intelligence (AI) for scientific discovery in the field of stem cell research was recently reported1, reflecting the continued growth of the technology and stressing the need for clarification on patents for AI-generated work. Kanda et al. created a humanoid robotic AI system that can plan and execute experiments to develop optimized protocols for differentiation of stem cells into desired therapeutically relevant cell types. In particular, the system tested cell culture conditions for differentiation of induced pluripotent stem cells (iPSCs) into retinal pigment epithelial cells (iPSC-RPE cells) based on a pre-optimized protocol, evaluated the results of particular cell culture conditions by image analysis of pigment producing cells, and planned the next experiments based on the results to develop an improved protocol for producing iPSC-RPE cells. The AI system tested 143 different conditions from 200 million possible parameter combinations in 111 days to achieve 88% better iPSC-RPE generation compared to the preexisting protocol. Accordingly, Kanda et al. concluded that the robotic AI system could drastically accelerate "systematic and unbiased exploration of experimental search space, suggesting immense use in medicine and research."

A robotic AI system has been developed by scientists that is capable of improving stem cell procedures that are utilized in regenerative medicine. The development of the robotic AI system was carried out by a joint research group led by Genki Kanda at the RIKEN Center for Biosystems Dynamics Research (BDR). The peer-reviewed research was published in the scientific journal eLife last week. One example of the AI system's utilization is having correctly determined the conditions necessary for regrowing retina layers in the eye, which is vital for vision. There were about 200 million possible conditions in which the AI controlled a trial and error process, according to the study.